Molecular Consequences and Targeting of PPM1D Overexpression in Myeloproliferative Neoplasms.

Activating PPM1D mutations are present in 3.1% of MPN patients and PPM1D overexpression is common in most PPM1D wild-type cases.

• Why it matters: Understanding PPM1D's role in MPN is important because its mutations and overexpression may influence disease progression and treatment response, especially in therapy-related cases.
• What they did: Researchers sequenced 519 MPN patients, created isogenic iPSC lines, and performed single-cell RNA-sequencing, mutational, and protein analyses to investigate PPM1D's impact and potential therapies.
• The result: Dual PPM1D and HDM2 inhibition reduced mutated clones and leukemic burden, suggesting this combination as a promising targeted treatment for myelofibrosis patients.